Department of pneumology, Hospital Clinic of Barcelona, Spain.
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
BMJ. 2021 Dec 6;375:e065871. doi: 10.1136/bmj-2021-065871.
Severe pneumonia is associated with high mortality (short and long term), as well as pulmonary and extrapulmonary complications. Appropriate diagnosis and early initiation of adequate antimicrobial treatment for severe pneumonia are crucial in improving survival among critically ill patients. Identifying the underlying causative pathogen is also critical for antimicrobial stewardship. However, establishing an etiological diagnosis is challenging in most patients, especially in those with chronic underlying disease; those who received previous antibiotic treatment; and those treated with mechanical ventilation. Furthermore, as antimicrobial therapy must be empiric, national and international guidelines recommend initial antimicrobial treatment according to the location's epidemiology; for patients admitted to the intensive care unit, specific recommendations on disease management are available. Adherence to pneumonia guidelines is associated with better outcomes in severe pneumonia. Yet, the continuing and necessary research on severe pneumonia is expansive, inviting different perspectives on host immunological responses, assessment of illness severity, microbial causes, risk factors for multidrug resistant pathogens, diagnostic tests, and therapeutic options.
严重肺炎与高死亡率(短期和长期)以及肺内和肺外并发症相关。对于重症患者,适当的诊断和早期开始充分的抗菌治疗对于提高生存率至关重要。确定潜在的病原体对于抗菌药物管理也至关重要。然而,在大多数患者中确定病因诊断具有挑战性,尤其是在那些患有慢性基础疾病的患者、那些接受过先前抗生素治疗的患者以及那些接受机械通气治疗的患者。此外,由于抗菌治疗必须是经验性的,因此国家和国际指南建议根据所在地的流行病学情况进行初始抗菌治疗;对于入住重症监护病房的患者,可提供有关疾病管理的具体建议。遵循肺炎指南与严重肺炎的更好结果相关。然而,对严重肺炎的持续和必要的研究是广泛的,它邀请了不同的观点来探讨宿主免疫反应、疾病严重程度评估、微生物病因、耐多药病原体的危险因素、诊断检测和治疗选择。